| High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster S Jasra, O Giricz, R Zeig-Owens, K Pradhan, DG Goldfarb, ... Nature medicine 28 (3), 468-471, 2022 | 32 | 2022 |
| The evolving role of next generation sequencing in myelodysplastic syndromes TP Spaulding, SS Stockton, MR Savona British Journal of Haematology 188 (2), 224-239, 2020 | 25 | 2020 |
| Refractory macrocytic anemias in patients with clonal hematopoietic disorders and isolated mutations of the spliceosome gene ZRSR2 RA Fleischman, SS Stockton, CR Cogle Leukemia Research 61, 104-107, 2017 | 11 | 2017 |
| Patient-specific comorbidities as prognostic variables for survival in myelofibrosis AL Sochacki, CA Bejan, S Zhao, A Patel, A Kishtagari, TP Spaulding, ... Blood Advances 7 (5), 756-767, 2023 | 8 | 2023 |
| The vascular disrupting agent OXi4503 in relapsed and refractory AML and MDS SS Stockton, L Pettiford, C Cline, D Chaplin, JW Hsu, JR Wingard, ... Blood 126 (23), 4936, 2015 | 7 | 2015 |
| Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk A Kishtagari, MAW Khan, Y Li, C Vlasschaert, N Marneni, AJ Silver, ... Blood Cancer Journal 14 (1), 6, 2024 | 4 | 2024 |
| Clonal Hematopoiesis and Inflammation in the VasculaturE (CHIVE): a prospective, longitudinal clonal hematopoiesis cohort and biorepository ML Shannon, JB Heimlich, S Olson, A Debevec, Z Copeland, A Kishtagari, ... Blood Advances, 2024 | 3 | 2024 |
| Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration S Das, SS Stockton, SA Hassan The Oncologist 28 (7), 575-583, 2023 | 2 | 2023 |
| Patient specific comorbidities impact overall survival in myelofibrosis A Sochacki, CA Bejan, S Zhao, T Spaulding, S Stockton, A Silver, ... Blood 134, 2959, 2019 | 2 | 2019 |
| Gene mutations in MDS associating with peripheral blood count abnormalities SS Stockton, V Malhotra, X Lu, M Thangavelu, M Albitar, CR Cogle Blood 126 (23), 1685, 2015 | 2 | 2015 |
| Clonal hematopoiesis and inflammation in the vasculature: CHIVE, a prospective, longitudinal clonal hematopoiesis cohort and biorepository ML Shannon, JB Heimlich, S Olson, A Debevec, Z Copeland, A Kishtagari, ... Blood Advances 8 (13), 3453-3463, 2024 | 1 | 2024 |
| Evolving or immutable-phase I solid tumor trials in the era of precision oncology SS Stockton, GD Ayers, C Lee, H Laferriere, S Das, J Berlin Investigational New Drugs, 1-9, 2024 | 1 | 2024 |
| Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE), a Prospective, Longitudinal Clonal Hematopoiesis Cohort and Biorepository J Heimlich, M Shannon, S Olson, AJ Silver, A Debevec, Z Copeland, ... Blood 142, 5594, 2023 | 1 | 2023 |
| Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial S Stockton, P Catalano, SJ Cohen, BA Burtness, EP Mitchell, E Dotan, ... The Oncologist 28 (9), 827-e822, 2023 | 1 | 2023 |
| JAK2V617F Clonal Hematopoiesis Stratifies By Peripheral Blood Counts. A Sochacki, S Zhao, CA Bejan, T Spaulding, S Stockton, A Silver, ... Blood 134, 1203, 2019 | 1 | 2019 |
| A phase I study of irinotecan combined with BAY1895344 (ATR inhibitor) in advanced solid tumors: Results of ETCTN 10402 dose escalation. TR Heumann, S Stockton, M Cecchini, R Aljumaily, C Shyr, J Whisenant, ... Journal of Clinical Oncology 42 (16_suppl), 3077-3077, 2024 | | 2024 |
| A phase I study of ATR inhibitor BAY1895344 (elimusertib) plus topotecan (ETCTN 10402): Results of dose escalation. S Stockton, C Shyr, M Cecchini, R Aljumaily, TR Halfdanarson, ... Journal of Clinical Oncology 42 (16_suppl), 3076-3076, 2024 | | 2024 |
| A phase 2 single-arm study of berzosertib in combination with irinotecan in patients with progressive TP53 mutant gastric and gastro-esophageal junction cancer. S Stockton, HP Soares, F Dayyani, A Saeed, ES Kim, N Jin, GH Yacoub, ... Journal of Clinical Oncology 41 (16_suppl), 4044-4044, 2023 | | 2023 |
| Phase I solid tumor trials (PHIstt) in the era of precision oncology (PO): A systematic survey. S Stockton, GD Ayers, CL Lee, HE Laferriere, J Berlin, S Das Journal of Clinical Oncology 41 (16_suppl), e13603-e13603, 2023 | | 2023 |
| Phase Ia/Ib Study of BAY1895344 Plus Topoisomerase I Inhibitors with a Focus on Poorly Differentiated Neuroendocrine Carcinomas and Pancreatic Adenocarcinoma S Stockton, AG Dan, M Cecchini, R Ajumaily, J Whisenant, S Gore, P Ivy, ... Endocrine Abstracts 89, 2023 | | 2023 |
